Susana Esteban

Dr. Susana Esteban

Laboratory of Neurophysiology, Biology Department, University of Balearic Islands (UIB), Ctra. Valldemossa Km 7,5 E-07122 Palma de Mallorca, Spain
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
MRMargarita R. Ramis
Margarita R. Ramis
SESusana Esteban
Susana Esteban
AMAntoni Miralles
Antoni Miralles
DTDunxian Tan
Dunxian Tan
Russel ReiterRussel Reiter
Russel Reiter

30 January 2018 in Current Neuropharmacology
Verified
Journal Article
Open access
FSFiorella Sarubbo
Fiorella Sarubbo
SESusana Esteban
Susana Esteban
AMAntoni Miralles
Antoni Miralles
DMDavid Moranta
David Moranta
Classically the oxidative stress and more recently inflammatory processes have been identified as the major causes of brain aging. Oxidative stress and inflammation affect each other, but there is more information about the effects of oxidative stress on aging than regarding the contribution of inflammation on it. In the intense research for methods to delay or mitigate the effects of aging, are interesting polyphenols, natural molecules synthesized by plants (e.g. resveratrol). Their antioxidant and anti-inflammatory properties become them useful molecules in the prevention of aging. The antiaging effects of polyphenols could be due to several related mechanisms, among which are the prevention of oxidative stress, SIRT1 activation and inflammaging modulation, via regulation of some signaling pathways, such as NF-κB. In this review, we describe the positive effects of polyphenols on the prevention of the changes that occur during aging in the brain and their consequences on cognition, emphasizing the possible modulation of inflammaging by polyphenols through a SIRT1-mediated mechanism.

13 August 2015 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MRM. R. Ramis
M. R. Ramis
SESusana Esteban
Susana Esteban
AMAntoni Miralles
Antoni Miralles
DTDun-Xian Tan
Dun-Xian Tan
RRR. J. Reiter
R. J. Reiter
Oxidative damage is related to aging and a wide range of human disorders. Mitochondria are in large part responsible for free radical production and they are also main targets of the attack of these toxic molecules. The resulting deleterious effects of the damage to mitochondria can be prevented by antioxidants. Melatonin is an endogenouslyproduced indoleamine that modulates numerous functions, including mitochondria-related functions; this result from its capacity to penetrate all morphophysiological barriers and to enter all subcellular compartments due to its amphiphilic nature. Furthermore, this indoleamine and its metabolites are powerful antioxidants and scavengers of free radicals, protecting cellular membranes, the electron transport chain and mitochondrial DNA from oxidative damage. These properties may make melatonin a potent protector against a variety of free radical-related diseases. By comparison, other conventional antioxidants have less efficacy due to their limited access to the mitochondria. In recent years, research has focused on the advancement of mitochondria-targeted antioxidants, such as MitoQ (composed by the lipophilic triphenylphosphonium cation conjugated to the endogenous antioxidant coenzyme Q10) and MitoE (composed by the triphenylphosphonium cation attached to the antioxidant α-tocopherol). Mitochondria-targeted antioxidants accumulate in several hundred-fold greater concentrations within mitochondria and protect these critical organelles from oxidative damage. Melatonin also seems to be a mitochondria-targeted antioxidant and has similar protective actions as the synthetic antioxidants. Further work is required to determine the therapeutic properties of these antioxidants in ameliorating diseases related to mitochondrial dysfunction.

1 December 2004 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SESusana Esteban
Susana Esteban
M. Cristina NicolauM. Cristina Nicolau
M. Cristina Nicolau
AGAntonio Garmundi
Antonio Garmundi
RRRubén Víctor Rial
Rubén Víctor Rial
Ana RodriquezAna Rodriquez
Ana Rodriquez
CICarmen Barriga Ibars
Carmen Barriga Ibars

14 August 2017 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
FSFiorella Sarubbo
Fiorella Sarubbo
MRM. R. Ramis
M. R. Ramis
CKC. Kienzer
C. Kienzer
SAS. Aparicio
S. Aparicio
SESusana Esteban
Susana Esteban
DMDavid Moranta
David Moranta

1 January 2007 in Brain Research Bulletin
Verified
Journal Article
Closed access
STS. Tejada
S. Tejada
Antoni SuredaAntoni Sureda
Antoni Sureda
CRC. Roca
C. Roca
AGAntonio Gamundí
Antonio Gamundí
SESusana Esteban
Susana Esteban